In conclusion, we suggest that YES1 mutation status should be assessed before EGFR‐TKIs treatment in patients with NSCLC harboring EGFR sensitive mutation in clinical practice, and we believe that clinical research and trials of dasatinib combined with EGFR‐TKIs in the use of patients with concurrent alteration of YES1 amplification and EGFR mutation‐positive are warranted in the future. This evidence concerns the gene EGFR and non-small cell lung carcinoma.